The cost effectiveness of pain management strategies in advanced cancer by Meads, DM et al.
1 
 
Full Title: The Cost-Effectiveness of Pain Management Strategies in Advanced 
Cancer 
 
Short title: Cost-Effectiveness of Pain Management 
 
David M. Meads1, John L. O’Dwyer1, Claire T. Hulme1, Rocio Rodriguez Lopez1, Michael I. 
Bennett2,3 
 
 
1 Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of 
Leeds, UK 
2Academic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, 
UK 
3St Gemma’s Academic Unit, St Gemma’s Hospice, Leeds, UK 
 
Address for correspondence: 
Dr David Meads 
Academic Unit of Health Economics, Leeds Institute of Health Sciences 
Worsley Building, Clarendon Way 
University of Leeds 
Telephone: +44 0113 343 0860 
Email: D.Meads@leeds.ac.uk; 
http://medhealth.leeds.ac.uk/profile/600/614/david_meads 
 
 
2 
 
Abstract 
Objectives: Uncontrolled pain in advanced cancer is a common problem and has significant 
impact on individuals’ quality of life and use of healthcare resources. Interventions to help 
manage pain at the end of life are available but there is limited economic evidence to support 
their wider implementation. We conducted a case study economic evaluation of two pain self-
management interventions (PainCheck and Tackling Cancer Pain Toolkit (TCPT)) compared 
to usual care.  
Methods: We generated a decision-analytic model to facilitate the evaluation. This modelled 
the survival of individuals at the end of life as they moved through pain severity categories. 
Intervention effectiveness was based on published meta-analyses results. The evaluation was 
conducted from the perspective of the UK health service provider and reported cost per 
quality-adjusted life year (QALY).  
Results: PainCheck and TCPT were cheaper (respective incremental costs -GBP148 [-
EUR168.53] and -GBP474 [-EUR539.74]) and more effective (respective incremental QALYs 
of 0.010 and 0.013) than usual care. There was a 65% and 99.5% chance of cost-
effectiveness for PainCheck and TCPT, respectively. Results were relatively robust to 
sensitivity analyses. The most important driver of cost-effectiveness was level of pain 
reduction (intervention effectiveness). Although cost savings were modest per patient these 
were considerable when accounting for the number of potential intervention beneficiaries. 
Conclusion: Educational and monitoring/feedback interventions have the potential to be cost-
effective. Economic evaluations based on estimates of effectiveness from published meta-
analyses and using a decision modelling approach can support commissioning decisions and 
implementation of pain management strategies.  
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Background 
 
Towards the end of life a significant proportion of cancer patients experience severe pain.(1, 
2) A European survey of 5,000 cancer patients found that 72% experienced pain, 90% of 
which was of moderate-to-severe intensity.(2)  Inadequate management of pain at the end of 
life is likely to have a significant detrimental impact on quality of life (3) and may lead to 
increased healthcare costs through unplanned hospital visits and admissions.(4) Indeed, one 
study indicated that poor pain control is the most frequent reason that cancer patients at home 
need emergency medical help.(5) Clearly, achieving good pain management at the end of life 
is a priority but service provision in this regard often falls short and interventions that are known 
to be effective are poorly implemented.  
There is growing evidence that self-management strategies facilitated by better 
communication, pain assessment and patient education can lead to improved pain 
outcomes.(6, 7) However, economic evidence for these types of interventions is less 
abundant. Despite the acknowledgement that economic evidence is key to improving access 
to effective palliative care (8, 9) evaluations are still relatively rare in this context (9, 10) and 
evaluations in the more specific context of pain at the end of life are rarer still.(11)  
We sought to generate evidence on the cost-effectiveness of pain self-management strategies 
at the end of life by conducting evaluations of case study interventions. Improving the 
Management of Pain from Advanced Cancer in the Community (IMPACCT) is a UK research 
programme aimed at the development and testing of interventions for patients at home to 
facilitate improved pain outcomes through self-management when delivered in addition to 
routine community palliative care services. The Tackling Cancer Pain Toolkit (TCPT) is a small 
booklet and DVD containing information on pain and medicines, alongside self-directed 
learning activities and sources of further information. PainCheck is an internet based pain 
monitoring system that enables patients to communicate pain data to health professionals 
routinely. The system alerts professionals when pain scores are above specific thresholds, 
and allows them to provde feedback through the system or contact patients directly for further 
assessment.  
Primary research evaluating the effectiveness of the IMPACCT interventions is on-going. The 
aim of the current research was to conduct economic evaluations of PainCheck and TCPT 
interventions when added to community palliative care delivery to estimate their value for 
money compared with usual care. The evaluation adopted a decision-analytic modelling 
approach incorporating published estimates of effectiveness from similar interventions and 
was designed to inform implementation strategies.  
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Methods 
The economic evaluation followed the NICE reference case (12) and hence was a cost-utility 
analysis with the primary outcome cost per incremental quality-adjusted life year (QALY) 
presented from the perspective of the UK healthcare and personal social services provider. 
The evaluation compared the PainCheck and TCPT pain management strategies in cancer 
patients at the end of life with usual care in this context. We defined usual care as routine care 
received by the patients at home from their local community palliative care team as determined 
by local policies and practices. As part of usual care in the UK, patients at the end of life with 
specialist needs (for example, poorly controlled pain) should be referred to community 
palliative care specialists and receive pain treatment and advice as part of that care. While 
this practice is increasing, services are highly variable across the UK and pain is often 
managed solely via GPs and community pharmacists. There is no set visit routine as patients 
access services as and when required but those on strong opiates will typically be reviewed 
2-3 times per month, depending on response. During these contacts with health care 
professionals, response is assessed with pain rating items (such as those in the Numeric Pain 
Rating Scale) and with less formal questions about pain. 
 
Decision model 
We developed a decision-analytic model to facilitate the economic evaluation, an earlier 
version of which has been previously described.(11) The decision model was a Markov cohort 
model the structure of which (Figure 1) was informed by patients, clinicians and other 
published decision models relating to pain. The model is structured around pain health states 
which are based on accepted 0-10 pain scale cut-offs: 0-4 = No/Mild Pain; 5-6 = Moderate 
Pain; 7-10 = Severe Pain.(13) More severe pain states are associated with higher costs due 
to emergency and unplanned healthcare resource use and poorer quality of life. The 
hypothetical cohort of patients (mean age = 72.4 based on the average age of IMPACCT 
survey respondents) transited through the model in weekly cycles until dying or until the end 
of the time horizon (one year). The model parameter values are presented in Table 1 and 
described below.  
 
Costs 
A costing of the IMPACCT interventions is provided in supplementary Table 1. Costs for TCPT 
related only to printing of the material (one off cost of GBP14.34 [EUR16.33]) and brief 
telephone contact with a nurse (weekly cost of GBP9.10 [EUR10.36]). Resources required for 
the provision of PainCheck were larger due mainly to programming requirements. PainCheck 
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incurred a one-off cost (covering maintenance programming, leaflet printing and nurse time to 
introduce the tool) of GBP49.01 [EUR55.81] and a weekly cost (covering nurse time for 
monitoring and patient response) of GBP24.47 [EUR27.86]. Only intervention implementation 
costs are included and those relating to intervention development are excluded. The health 
state costs (Table 1) are derived from the IMPACCT patient survey where respondents 
completed a questionnaire capturing primary and community (e.g. GP visits, nurse contact, 
etc.) and secondary or hospital (e.g. visits to A&E, hospice stays, etc.) care use in the previous 
month. Unit costs were obtained from national sources including the PSSRU Costs of Health 
and Social Care,(14) NHS Reference cost database and the British National Formulary (BNF). 
All costs are UK pounds and 2017 prices with equivalent Euro values provided in brackets 
using a historical currency converter (for June 30th 2017). 
 
Health state utility 
The utility values for the health states (Table 1) were derived from the IMPACCT patient survey 
in which respondents completed the EQ-5D-3L measure scored using the UK tariff.(15) We 
also conducted a sensitivity analysis where utilities were based on the EORTC-8D 
measure.(16) In view of the fact that the QALY framework has been criticised in palliative care 
(17), we conducted another analyses based on the ICECAP measure (18) which adopts the 
capability framework but which may enable cost-utility analyses. 
 
Transition probabilities 
 
Meta-review of educational and monitoring interventions  
We conducted a meta-review of educational and feedback/monitoring interventions for 
improving cancer pain at the end of life. We searched for randomised controlled trials (RCTs) 
of non-pharmacological interventions in advanced cancer pain and for reviews in this area. 
We searched Embase Classic and Embase 1947-2017; Ovid MEDLINE(R) 1946-2017; 
MEDLINE(R) In-Process & Other Non-Indexed Citations. Searches were conducted in 
February 2017. We short-listed and reviewed those studies reporting a systematic review of 
either educational or feedback/monitoring interventions for pain. Non-English language 
publications were excluded. Two researchers reviewed abstracts and differences were 
resolved by consensus meeting. The shortlisted publications were discussed with a clinician 
to identify which best reflected the properties of the IMPACCT interventions and hence were 
suitable proxy estimates of effectiveness. In particular, we were interested in studies of 
interventions that encouraged self-management (as opposed to having significant levels of 
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health care professional input). In identifying a suitable review study, we assessed their 
inclusion criteria to ensure this aligned with the two IMPACCT interventions.  
Candidate studies had to report synthesised estimates of effectiveness (and standard 
error/deviation). Effectiveness had to be based on the Numeric Pain Rating Scale (NPRS)(19). 
The NPRS is a reliable and valid, self-complete measure of pain. Responses are captured on 
an 11-point numeric scale ranging from '0' (i.e. “no pain”) to '10' (i.e. “pain as bad as you can 
imagine”). NPRS questions cover worst intensity, least intensity and average intensity (over 
the last 24 hours). Our review specifically attempted to identify reports of average pain 
intensity as this item was also included in the IMPACCT patient survey and was the basis of 
health state parameters. We also considered RCTs that were published after reviews had 
been completed.  
 
Effectiveness, pain progression and survival 
The initial distribution between the pain severity groups was determined by the IMPACCT 
patient survey (Table 1). Effectiveness translated into health state transition probabilities by 
observing the pain category change in the IMPACCT survey respondents following the 
relevant pain reductions. Intervention effects (rather, a sixth of) were assumed to occur on an 
incremental basis for six weeks after which pain levels were maintained. In the usual care arm 
pain was assumed to progress over time. Progression was based on a multinomial regression 
model predicting change in EQ-5D-3L pain/discomfort item response over time and after 
controlling for survival in a recent trial including cancer patients at the end of life.(20)  
The survival of the cohort was estimated using parametric regression which was fitted to other 
IMPACCT data. The data (n=4,638; 84% with a cancer diagnosis) was retrospectively 
collected on all patient referrals to specialist palliative care services in the city of Leeds, UK 
over 2 years (2012-2014). The sample had a mean survival of 80.77 days (SD=117.81). A 
number of models were applied to the data including exponential, Weibull and Gompertz. 
Based on best visual fit with the observed Kaplan-Meier curve and lowest Akaike information 
criterion (AIC) value, Weibull was selected. As the gamma factor was significant the use of 
the Weibull model is justified as this indicates a non-constant (and declining) hazard function. 
The same risk estimates from this analysis were applied to all health states. The survival 
model estimates were permitted to vary in the probabilistic sensitivity analysis following 
Cholesky decomposition for correlated regression parameters. During the 52-week model time 
horizon, 97% of the cohort were expected to have died. Although there is some evidence that 
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pain can independently explain survival, the evidence is mixed (21) and thus here we assumed 
they are unrelated.  
Analysis 
Cost-effectiveness was assessed based on Incremental Cost-Effectiveness Ratio (ICER) and 
Incremental Net Monetary Benefit (INMB) values. These were generated separately for 
PainCheck and TCPT in pairwise comparisons versus usual care. A fully incremental analysis 
was not conducted since these interventions might be used in combination. To test this, a 
further analysis evaluated receipt of the combined active interventions. The NICE willingness 
to pay per incremental QALY threshold ([λ] =GBP20,000 [EUR22,774]) was adopted with 
ICERs below this figure indicating cost-effectiveness. The INMB is a transformation of the 
ICER where positive INMB values indicate cost-effectiveness; INMB was calculated thus: 
𝐼𝑁𝑀𝐵 = (𝜆 ∗ ∆𝐸) − ∆𝐶 
A range of one-way, deterministic sensitivity analyses were conducted where alternative 
model parameter values or assumptions were applied and their impact on cost-effectiveness 
observed. The deterministic sensitivity analyses tested: basing effectiveness on the upper 
confidence interval of pain reduction values from meta-analyses (i.e. assuming reduced 
effect); assuming an additional cost (10% of the cohort receiving a nurse visit) in the 
PainCheck and TCPT arms; assuming that 50% of those in the PainCheck and TCPT arms 
experienced pain progression (at usual care rate) after six weeks rather than maintaining pain 
levels; assuming the starting cohort all had either moderate or severe pain (no mild cases); 
basing QALY calculations on the EORTC-8D and ICE-CAP; and removing the half cycle 
correction. We conducted additional analyses exploring the impact of using costs from 
individual studies identified by the systematic reviews. For PainCheck, a U.S. study was used 
as an alternative source of intervention costs (22) and for TCPT we used a Dutch study (23); 
these were chosen from the review as they had relatively large sample sizes, levels of 
effectiveness similar to the overall mean and as they reported the resources required to deliver 
the interventions (see Error! Reference source not found.).        
We also conducted threshold analyses to establish the costs and effectiveness required to 
achieve cost-effectiveness. We conducted a probabilistic sensitivity analysis (PSA) to 
characterise overall parameter uncertainty in the model by assigning probability distributions 
to each of the input parameters, and randomly drawing from these probabilities over the 
10,000 Monte Carlo simulations, yielding 10,000 estimates of ICERs and INMB. PSA results 
were plotted on the cost-effectiveness plane and INMB estimates used to generate the cost-
effectiveness acceptability curve (CEAC)(24) The CEAC illustrates the probability that each 
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intervention would be cost-effective given a range of willingness-to-pay thresholds. 
Discounting was not required as all costs and benefits were experienced within one year. A 
half-cycle correction was applied buta sensitivity analysis was also conducted where no half-
cycle correction was applied 
Finally, we explored the value of further research by conducting a value of information (VoI) 
analysis which attaches a formal cost to the uncertainty in the cost-effectiveness results.(25) 
We estimated population level expected value of perfect information (EVPI) which required 
information on the number of patients who could benefit from the interventions (incidence and 
number of years the decision is relevant for). According to national data, 149,152 people die 
each year of cancer in England.(26) Based on European survey results (2) indicating that 72% 
have pain which in 90% of cases is moderate/severe, yields a relevant annual population of 
96,650. We assumed that the decision problem was relevant for 10 years and we discounted 
values beyond one year based on a 3.5% discount rate. We used the Sheffield Accelerated 
Value of Information (SAVI) tool(27) to estimate the Expected Value of Perfect Parameter 
Information (EVPPI) for single parameters. Using the incidence figures we also estimated the 
budget impact of implementing the interventions over the same period. All analyses were 
conducted in Stata IC software (version 14; StataCorp) and Excel (Microsoft). 
 
Results 
The PRISMA flow diagram for the literature review is included in supplementary material 
(Supplementary figure 1). Seventeen reviews (Supplementary Table 3) were identified and 
discussed with the lead clinician. Reviews were not deemed suitable for a number of reasons 
including: not synthesising study results (e.g.(6, 28)); including non-cancer studies (e.g.(29)); 
having a restricted population (30); being superseded by more recent reviews (31); or 
synthesising outcomes from studies investigating interventions comprising a significant 
element of face-to-face health-care professional delivery(32-34).  Results from a review and 
meta-analysis of pain assessment and feedback interventions was thought a suitable proxy 
for the effectiveness of PainCheck.(35) The meta-analysis estimated mean reductions in pain 
ratings of -0.59 (Lower CI =-0.87; Upper CI =-0.3). These figures led to a 0.46 and a 0.39 
probability of transiting from Moderate to No/Mild pain and Severe to Moderate pain 
categories, respectively, over six weeks. The meta-analysis selected as a proxy for TCPT 
intervention (36) estimated mean reductions in pain ratings of -1.1 (Lower CI =-1.8; Upper CI 
=-0.41). These figures led to a 0.56 and 0.51 probability of transiting from Moderate to No/Mild 
pain and Severe to Moderate pain categories, respectively, over six weeks. We could not 
identify a study that would provide a reasonable approximation of the joint effectiveness of 
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PainCheck and TCPT thus we made assumption that this was: -1.1 + (-0.59*0.5) or -1.395. 
We tested this value in the model in a comparison with usual care but included the full costs 
for both active interventions.  
The results from the base case and sensitivity analyses are included in Table 2. PainCheck 
and TCPT were both cost-saving and more effective than (i.e. they dominated) usual care. 
However, TCPT led to greater NMB. In general, the incremental costs and benefits were 
modest. Sensitivity analyses exploring alternative utility values, costs and maintenance of 
effect after six weeks in most cases did not change the conclusion for either intervention. Only 
changes to the levels of effectiveness substantively altered the results. Using the upper 
confidence interval from the respective meta-analyses led to PainCheck no longer being cost-
effective while TCPT remained cost-effective. Adopting alternative intervention costs (and 
effects) from individual studies from within the systematic reviews had the same effect. 
Threshold analyses indicated, all else being equal and at current costs, PainCheck requires a 
pain reduction of at least 0.50 to remain cost-effective; at current levels of effectiveness, 
PainCheck is cost-effective up to one-off intervention cost of GBP401.86 [EUR457.59] or 
weekly intervention costs of GBP58.25 [EUR66.33] being incurred. At current costs TCPT 
requires a pain reduction of at least 0.40 to remain cost-effective; at current levels of 
effectiveness TCPT is cost-effective up to one-off intervention costs of GBP744.61 
[EUR847.88] or weekly intervention costs of GBP43.44 [EUR49.46] being incurred. The 
combined intervention was cost-effective but represented less value for money than TCPT 
alone. 
The probabilistic results yielded similar results to those from the deterministic analyses 
although INMB is reduced. A higher number of simulations in the TCPT arm were cost-saving 
vs. usual care than is the case with PainCheck. In both comparisons, all simulations showed 
positive QALY gain over usual care. The cost-effectiveness planes (Figure 2) indicates the 
spread of ICERs from the Monte Carlo simulations, representing parameter uncertainty. The 
cost-effectiveness acceptability curves (Supplementary Figure 2) indicate that PainCheck has 
a 65% chance of being the cost-effective option and TCPT a 99.5% chance of being cost-
effective at a willingness to pay threshold of GBP20,000 [EUR22,774] per QALY.  
For PainCheck, the population EVPI per year was GBP2,945,026 [EUR3,353,460] and 
GBP24,592,210 [EUR28,002,805] over 10 years indicating a significant cost of uncertainty in 
the decision. Given that TCPT was highly likely to be cost-effective, the population EVPI was 
low (GBP10,464 [EUR11,915] per year) indicating further research on the topic may be 
unnecessary. The EVPPI figures for TCPT were effectively zero given the lack of uncertainty 
in the decision. They were also zero for PainCheck parameters except for the severe and 
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moderate pain health state costs. The cost of decisional uncertainty surrounding the moderate 
health state cost was GBP971,100 [EUR1,105,778] over ten years. This was much higher for 
the severe health state cost parameter (GBP15,590,000 [EUR17,752,115]) and the magnitude 
suggests additional research into the cost of cancer pain may be warranted. The budget 
impact estimates indicate that PainCheck would lead to savings of GBP663,831 
[EUR755,895] per year or GBP5,543,272 [EUR6,312,046] over 10 years. The estimated cost 
savings for TCPT were estimated to be GBP23,369,253 [EUR26,610,241] per year and 
GBP195,143,121 [EUR222,206,740] over 10 years.  
 
Discussion 
These analyses represent the most comprehensive assessment to date of the value for money 
of pain management interventions at the end of life. Using a decision modelling approach, we 
compared two types of intervention (educational and pain monitoring/feedback) against usual 
care from the perspective of the health and social care provider. We relied on estimates of 
effectiveness from published meta-analyses. PainCheck and TCPT are relatively inexpensive 
and the evaluations suggest that both have the potential to be cost-effective. Indeed, in the 
base case analyses, both interventions were cheaper and more effective than usual care. The 
conclusions were relatively robust to a number of sensitivity analyses. The effectiveness 
parameter appeared relatively more influential in determining cost-effectiveness than 
intervention costs or utility values. Assuming all patients were either in moderate or severe 
pain improved the benefit of the IMPACCT interventions noticeably. A scenario where both 
interventions were received would be a worse strategy than implementing TCPT alone, mainly 
due to the additional costs of PainCheck. However, assumptions were made here on the level 
of combined effect.  
Although the use of the generic QALY framework (based on EQ-5D) to evaluate palliative care 
interventions has been questioned (17), here the use of condition specific QALY (EORTC-8D) 
and capability-based approaches (ICE-CAP) yielded reduced incremental benefits for the 
active interventions. It is possible that the EQ-5D fails to capture additional benefits this patient 
group may experience following improved pain management such as a greater feeling of 
control and the emotional positives that come with being able to stay at home. However, the 
EQ-5D appears adept at discriminating between people based on pain level and this may 
explain the relative performance of the utility measures as the decision-model is predicated 
on pain categories. 
The probabilistic analyses suggest that both PainCheck and TCPT are highly likely to deliver 
QALY gains over usual care. However, in both cases, the interventions were less likely to lead 
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to cost-savings. Incorporating parameter uncertainty in the model suggests that PainCheck 
and TCPT have 65% and 99.5% chance of being cost-effective, respectively. The greater 
uncertainty surrounding PainCheck relates to the higher cost and lower assumed effect. The 
Value of Information analysis suggest that additional research on PainCheck is warranted and 
the EVPPI values indicate that reducing uncertainty surrounding cost estimates should be a 
focus.   
The costs predicted here are similar although lower than those presented in a recent 
publication.(37) However, we used a different definition of end of life and much lower survival 
periods. Although the cost savings associated with each intervention were modest, values for 
the estimated population are potentially substantial (GBP5,543,272 [EUR6,312,046] and 
GBP195,143,121 [EUR222,206,740]  over 10 years for PainCheck and TCPT, respectively).  
Limitations 
We did not have direct estimates of the effectiveness of either active case study interventions 
evaluated here and relied on synthesised estimates from meta-analyses. While the studies 
employed in the analyses as the basis of effectiveness estimates were selected following a 
meta-review and due consideration, it is possible that these reviews incorporate studies that 
are not accurate reflections of the PainCheck and TCPT interventions. It is possible that these 
reviews and synthesised outcomes derive from disparate study interventions or designs which 
may have biased results. Adam and colleagues(35), reviewing patient feedback/monitoring 
studies, found most were prone to some element of bias and that two studies contributing to 
the synthesis should be treated with caution. As the effectiveness estimates in those two 
studies were above the mean, their exclusion would reduce the assumed overall effectiveness 
(albeit slightly given study weightings) for PainCheck. While there were very few reviews 
relating to patient feedback/monitoring, there were several targeting educational interventions. 
The review by Bennett and colleagues was selected based on appropriateness of their study 
inclusion criteria. There is limited information in the review of the quality of studies included 
and potential for bias. Examination of study outcomes indicates the presence of significant 
heterogeneity with one outlier study reporting a very large intervention effect and this may 
have biased results. However, it is worth pointing out that the uncertainty in outcome should 
be captured in the probabilistic sensitivity analyses presented here. Furthermore, excluding 
that study from the weighted mean still yielded an effect greater than that required (-0.40) for 
TCPT to be cost-effective. Although, of course, this is based on the use of costs estimated 
here for the TCPT intervention. It is also possible that there may be individual randomised 
controlled trials that better reflect the potential effect of either active intervention.  
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Although it has been suggested that informal care costs are an important consideration in 
palliative care economic evaluations (38) we did not include these in the current analyses. We 
wished to adhere to the NICE reference case which excludes these costs but, more 
importantly, we did not have health state data relating to informal care costs. It is likely that 
carers of patients in higher pain categories incur higher costs; thus, adopting a broader 
perspective and including informal care costs would likely increase the estimates of value for 
money for PainCheck and TCPT. However, increased self-management may also increase 
informal care requirements and further research is needed to explore this. 
Further research and implications 
The decision model generated and tested here is robust and may be a tool that, following 
adaptations, has other useful applications in this palliative care. It may also be useful for local 
decision makers considering commissioning alternative pain management strategies. The 
active interventions evaluated here have the potential to be cost-effective and additional 
research, for example, in the form of randomised trials or observational data collection and 
analysis, may be warranted to add to the evidence base. 
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Table 1: Model parameter values 
Parameter Mean  SE Distribution∞ Source 
     
Intervention costs 
  
 See supplementary 
Table 1 
One-off cost for TCPT  GBP14.34 
[EUR16.33] N/A – Fixed 
N/A - Fixed  
Weekly cost for TCPT GBP9.10 
[EUR10.36] N/A – Fixed 
N/A - Fixed  
One-off cost for PainCheck GBP49.01 
[EUR55.81] N/A – Fixed 
N/A - Fixed  
Weekly cost for PainCheck GBP24.27 
[EUR27.86] N/A – Fixed 
N/A - Fixed  
     
Health state costs 
(weekly)* 
Β  
 IMPACCT Patient 
survey (39) 
Constant (base= No/Mild 
Pain) 
GBP553.59 
[EUR630.37] 
GBP105.78 
[EUR120.45] 
Lognormal 
 
     
Moderate Pain 
GBP160.34 
[EUR182.58] 
GBP160.49 
[EUR182.75] 
Lognormal 
 
Severe Pain 
GBP341.54 
[EUR388.91] 
GBP203.93 
[EUR232.21] 
Lognormal 
 
     
Health state utility** 
β  
 EQ-5D - IMPACCT 
Patient survey (39) 
Constant (base= No/Mild 
Pain) 
0.525 0.029 Beta  
     
Moderate Pain -0.102 0.045 Gamma 
(decrement) 
 
Severe Pain -0.377 0.047 Gamma 
(decrement) 
 
Starting proportions    IMPACCT Patient 
survey (39) 
No/Mild pain 0.439 0.031 Dirichlet - Gamma  
Moderate pain 0.305 0.030 Dirichlet - Gamma  
Severe pain 0.256 0.028 Dirichlet - Gamma  
     
Intervention 
effectiveness***  
    
Standard care 0.0 N/A - Fixed N/A - Fixed Assumption 
PainCheck -0.59 0.143 Beta∆ (35) 
Tackling Cancer Pain toolkit -1.1 0.357 Beta∆ (36) 
     
     
Pain progression****    (20) 
No/Mild pain to Moderate 
pain 
0.004 0.002 Beta  
No/Mild pain  to Severe pain 0.002 0.001 Beta  
Moderate pain to Severe 
pain 
0.002 0.001 Beta  
     
Survival – Weibull 
parametric model***** 
   Palliative Care 
Referral Data(40) 
Gamma (_ln/p) -0.306 0.011 N/A^  
Constant -2.019 0.083   
Age 0.005 0.001   
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∞Distributions used in the probabilistic sensitivity analysis; ∆Pain reductions are first converted to 
probabilities based on likelihood of pain category change in IMPACCT survey respondents;^Uses 
estimates based on the regression covariance matrix; *Derived using generalised linear model (Gamma 
family, Log link); **derived using ordinary least squares regression; ***Change in pain rating scale vs. 
usual care;****Weekly probability applied only to standard care arm, all other transition probabilities 
assumed to be 0.0; *****Weekly mortality following referral to palliative care 
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Table 2: Cost-effectiveness results 
 
Analysis 
 
Total Cost 
Total 
QALY 
Incr. Cost  
Incr. 
QALY  
ICER (vs. 
Usual care) 
INMB 
Base case Analysis 
- deterministic 
      
PainCheck 
GBP7,532 
[EUR8,577] 
0.090 
-GBP148 [-
EUR169] 
0.010 
Dominates 
UC 
GBP354 
[EUR403] 
TCPT 
GBP7,207 
[EUR8,207] 
0.093 
-GBP474 [-
EUR540] 
0.013 
Dominates 
UC 
GBP731 
[EUR832] 
Usual Care 
GBP7,680 
[EUR8,745] 
0.080 -- -- -- -- 
Base case Analysis 
- probabilistic 
      
PainCheck 
GBP7,691 
[EUR8,758] 
0.088 
-GBP7 [-
EUR8] 
0.008 
Dominates 
UC 
GBP160 
[EUR182] 
TCPT 
GBP7,401 
[EUR8,427] 
0.089 
-GBP297 [-
EUR338] 
0.009 
Dominates 
UC 
GBP477 
[EUR543] 
Usual Care 
GBP7,698 
[EUR8,766] 
0.080 -- -- -- -- 
Combined 
interventions 
      
PainCheck+TCPT 
GBP7,500 
[EUR8,540] 
0.093 
-GBP181 [-
EUR206] 
0.013 
Dominates 
UC 
GBP440 
[EUR501] 
Sensitivity analyses       
       
Upper CI for 
effectiveness 
      
PainCheck (-0.30) -- -- 
GBP268 
[EUR305] 
0.002 GBP109,235 
[EUR124,384] 
-GBP219 
[EUR249] 
TCPT (-0.41) -- -- 
GBP44 
[EUR50] 
0.003 GBP15,465 
[EUR17,610] 
GBP13 
[EUR15] 
Assuming 10% 
receive nurse visit 
      
PainCheck -- -- 
-GBP143 [-
EUR163] 
0.010 Dominates 
UC 
GBP349 
[EUR397] 
TCPT -- -- 
-GBP469 [-
EUR534] 
0.013 Dominates 
UC 
GBP727 
[EUR827] 
Adopting 
intervention costs 
from other studies 
  
    
       
PainCheck   
GBP274 
[EUR312] 
0.010 GBP26,631 
[EUR30,324] 
-GBP68 [-
EUR77] 
       
TCPT   
-GBP362 [-
EUR412] 
0.013 Dominates 
UC 
GBP620 
[EUR706] 
       
Adopting 
intervention costs 
and effectiveness 
from other studies 
  
    
PainCheck   
GBP259 
[EUR295] 
0.010 GBP24,755 
[EUR28,188] 
-GBP50 [-
EUR57] 
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TCPT   
-GBP243 [-
EUR277] 
0.010 Dominates 
UC 
GBP453 
[EUR516] 
50% pain 
progression >6 
weeks for 
PainCheck/TCPT 
      
PainCheck -- -- 
-GBP108 [-
EUR122.98] 
0.010 Dominates 
UC 
GBP300 
[EUR342] 
TCPT -- -- 
-GBP430 [-
EUR489.63] 
0.012 Dominates 
UC 
GBP673 
[EUR766] 
Patients begin in 
moderate or Severe 
pain (50:50)  
      
PainCheck -- -- 
-GBP394 [-
EUR449] 
0.016 Dominates 
UC 
GBP710 
[EUR808] 
TCPT -- -- 
-GBP819 [-
EUR933] 
0.020 Dominates 
UC 
GBP1,228 
[EUR1,398] 
Using EORTC-8D 
Utilities 
      
PainCheck -- -- 
-GBP148 [-
EUR169] 
0.004 Dominates 
UC 
GBP233 
[EUR265] 
TCPT -- -- 
-GBP474 [-
EUR540] 
0.005 Dominates 
UC 
GBP579 
[EUR659] 
Using ICE-CAP 
Utilities 
      
PainCheck -- -- 
-GBP148 [-
EUR169] 
0.004 Dominates 
UC 
GBP228 
[EUR260] 
TCPT -- -- 
-GBP474 [-
EUR540] 
0.005 Dominates 
UC 
GBP573 
[EUR652] 
No half-cycle 
correction 
  
    
PainCheck -- -- 
-GBP143 [-
EUR163] 
0.010 
Dominates 
UC 
GBP348 
[EUR396] 
TCPT -- -- 
-GBP468 [-
EUR533] 
0.013 Dominates 
UC 
GBP725 
[EUR826] 
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Figure 1: Decision model structure 
 
Figure 2: Cost-effectiveness planes  
 
Supplementary figure 1: PRISMA diagram 
 
Supplementary figure 2: CEACs
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